LOGIN  |  REGISTER
Amneal Pharmaceuticals
Viking Therapeutics

OraSure Technologies to Participate in Upcoming Investor Conference

November 17, 2025 | Last Trade: US$2.43 0.05 1.89

BETHLEHEM, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference:

  • Stephens Annual Investment Conference on Wednesday, November 19, with a Q&A session scheduled for 10 a.m. CT

A live webcast and replay of the Q&A session will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations.

About OraSure Technologies, Inc. 

OraSure Technologies, Inc. (“OraSure” and “OTI”) transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. OTI improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OTI’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information, please visit www.orasure.com

Investor Contact:Media Contact:
Jason PlagmanAmy Koch
VP, Investor RelationsDirector, Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.
Viking Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page